Publication: Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest
Issued Date
2013-06-17
Resource Type
Language
eng
Bibliographic Citation
Journal of Oncology. 2012, ID 601682
Suggested Citation
Suwit Duangmano, Phorntip Sae-lim, Apichart Suksamrarn, Pimpichaya Patmasiriwat, Frederick E. Domann Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest. Journal of Oncology. 2012, ID 601682. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/2100
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest
Abstract
Purpose. To explore the effects of cucurbitacin B on the radiation survival of human breast cancer cells and to elucidate the cellular
mechanism of radiosensitization if any. Materials and Methods. Human breast carcinoma cell lines were treated with cucurbitacin
B before irradiation with 0–10Gy of 137Cs gamma rays. The effect of cucurbitacin B on cell-survival following irradiation was
evaluated by colony-forming assay. Cell cycle distributions were investigated using flow cytometry. Real-time PCR and western
blots were performed to investigate the expression of cell cycle checkpoints. Results. Cucurbitacin B inhibited breast cancer cell
proliferation in a dose-dependent manner. Only MDA-MB-231 and MCF7:5C cells but not SKBR-3 cells were radiosensitized by
cucurbitacin B. Flow cytometric analysis for DNA content indicated that cucurbitacin B resulted in G2/M arrest in MDA-MB-231
andMCF7:5C but not SKBR-3 cells.Moreover, Real-time PCR and western blot analysis demonstrated upregulated p21 expression
before irradiation, a likely cause of the cell cycle arrest. Conclusion. Taken together, these findings suggest that cucurbitacin B causes
radiosensitization of some breast cancer cells, and that cucurbitacin B induced G2/M arrest is an importantmechanism. Therefore,
combinations of cucurbitacin B with radiotherapy may be appropriate for experimental breast cancer treatment.